EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Differentiation Therapy in Acute Myeloid Leukemia: Advances in Phenotypic Screening and CRISPR-Based Functional Genomics

Shinichiro Takahashi

Acta Haematologica · 13.03.2026 · 1-22

DOI: 10.1159/000551445 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Acta Haematologica, online erschienen am 13.03.2026. Verfasst von Shinichiro Takahashi. Beteiligte Einrichtung: Division of Laboratory Medicine, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Sendai, Japan, shintakahashi@tohoku-mpu.ac.jp. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 55 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background: Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous malignancy characterized by a differentiation block in myeloid progenitors. Although advances in molecular targeted therapies have improved outcomes in selected subgroups, long-term prognosis remains poor for many patients. Differentiation therapy, exemplified by the success of all-trans retinoic acid in acute promyelocytic leukemia (APL), represents an alternative therapeutic paradigm that aims to overcome the differentiation blockade rather than directly inducing cytotoxicity. Summary: This review summarizes recent advances in phenotypic screening and CRISPR-based functional genomics that have contributed to the discovery of novel differentiation-inducing strategies in AML. High-throughput phenotypic screening approaches using compound libraries, computational tools, and integrative transcriptomic analyses have identified several candidate differentiation inducers. For example, triciribine, an AKT inhibitor, has been identified as a differentiation-inducing compound in AML models. In parallel, CRISPR loss- and gain-of-function screens have uncovered multilayered regulatory networks governing AML differentiation, including transcriptional regulators (e.g., KAT6A), metabolic dependencies (e.g., NMNAT1, glucose transporter type 1), and post-transcriptional regulators (e.g., ZFP36L2, YTHDC1). Emerging computational approaches, such as the Lineage Maturation Index and single-cell data integration, further enhance target prioritization and improve the translational relevance of screening results. Despite these advances, differentiation therapy outside APL remains challenging due to partial maturation, context-dependent responses, and AML heterogeneity. Key Messages: Recent advances in phenotypic screening and CRISPR-based functional genomics have expanded our understanding of the molecular mechanisms governing AML differentiation and have revealed novel therapeutic vulnerabilities. Integration of these discovery platforms with computational and single-cell approaches may facilitate the development of differentiation-based strategies for a broader spectrum of AML patients.

Schlagwörter

Stichwörter der Autor:innen

Acute myeloid leukemiaCRISPRDifferentiation therapyMetabolismPhenotypic screening

Autor:innen und Institutionen

  • Division of Laboratory Medicine, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Sendai, Japan, shintakahashi@tohoku-mpu.ac.jp.
  • Institute of Molecular Biomembrane and Glycobiology, Tohoku Medical and Pharmaceutical University, Sendai, Japan, shintakahashi@tohoku-mpu.ac.jp.

Zitieren

APA

Takahashi, S. (2026). Differentiation Therapy in Acute Myeloid Leukemia: Advances in Phenotypic Screening and CRISPR-Based Functional Genomics. Acta Haematologica, 1-22. https://doi.org/10.1159/000551445

Vancouver

Takahashi S. Differentiation Therapy in Acute Myeloid Leukemia: Advances in Phenotypic Screening and CRISPR-Based Functional Genomics. Acta Haematologica. 2026:1-22. doi:10.1159/000551445

BibTeX
@article{Takahashi2026,
  author = {Takahashi, Shinichiro},
  title = {Differentiation Therapy in Acute Myeloid Leukemia: Advances in Phenotypic Screening and CRISPR-Based Functional Genomics},
  journal = {Acta Haematologica},
  year = {2026},
  pages = {1--22},
  doi = {10.1159/000551445}
}
Kostenlos starten →